BioMarin Pharmaceutical, Inc.

( )
BMRN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -0.61%77.731.0%$1898.73m
AMGNAmgen, Inc. 3.00%211.581.3%$929.21m
REGNRegeneron Pharmaceuticals, Inc. 2.22%504.272.6%$852.10m
BIIBBiogen, Inc. 3.62%311.391.5%$796.11m
VRTXVertex Pharmaceuticals, Inc. 7.13%255.301.9%$652.54m
MRNAModerna, Inc. -0.57%34.640.0%$571.40m
ILMNIllumina, Inc. 5.51%278.013.5%$493.14m
ALXNAlexion Pharmaceuticals, Inc. 6.84%95.912.0%$303.02m
AAgilent Technologies, Inc. 5.47%74.281.6%$229.86m
INCYIncyte Corp. 8.30%85.112.5%$212.70m
EXASEXACT Sciences Corp. 11.70%62.2721.0%$179.74m
SGENSeattle Genetics, Inc. 6.83%124.476.1%$170.36m
BMRNBioMarin Pharmaceutical, Inc. -1.71%82.774.3%$160.44m
NVAXNovavax, Inc. 3.14%16.10114.7%$125.40m
IMMUImmunomedics, Inc. 99.79%18.7811.9%$114.76m

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.